BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Collins Foods to offload 20 Taco Bell outlets in Australia - 2Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- 3This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- 4Child influencers helped power a booming industry. It's time for a reckoning.
- 5Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- The architect of Iran’s military survival remains defiant
- Brazil's Bolsonaro to continue his sentence at home because of poor health
- Native Americans had dice and games of probability long before other cultures, study finds
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- 5 Bike Brands for Ordinary Use
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- An Extended time of Self-Reflection: Self-awareness through Journaling
- What's Your Number one Superhuman Film Made?
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
